We did not, you know, the size of the study is not enough to look for statistical significance, but we do expect that the new constructs will do a little bit better on key immunogenicity endpoints. And I'll concur. I think that the You know, we're basing moving forward with that study based on some of the preclinical data that's compelling. So look forward to having that data, top line data sometime this year.

May 13, 2025 / receipt, needs a key / Steve, CEO | earnings call 2025-05-13 | transcript 53370749-0e09-41cf-9ddf-f0a2e2dba865 | chars 22469-22882 | segment 22

No, I concur, Sean. I think that we're in the sweet spot now in terms of being able to control our destiny with production. We do have, as you mentioned, not just capacity but product on hand from the previous S-only construct that I look forward to future studies with more to follow.

Aug 8, 2022 / receipt, needs a key / James, other | earnings call 2022-08-08 | transcript 1762f97d-4371-4be5-9ab3-90ba8fe9beda | chars 26693-26978 | segment 27

In contrast, our vaccines are room temperature stable and provided in an oral format. This radically simplifies mass vaccination campaigns by enabling potentially self-administration at home without using any special equipment or trained personnel and removing the need to schedule and travel for appointments.

Aug 8, 2022 / receipt, needs a key / Dr. Sean Tucker, Founder and Chief Science Officer | earnings call 2022-08-08 | transcript 1762f97d-4371-4be5-9ab3-90ba8fe9beda | chars 8504-8814 | segment 8